Larry Miller

    Larry Miller
    General Counsel

    Larry Miller began serving as General Counsel in March 2024.  He brings over twenty years of experience in the biopharmaceutical industry. Most recently, he served as General Counsel and Secretary at Phathom Pharmaceuticals, Inc., where he provided strategic legal advice on securities, corporate governance, mergers and acquisitions, intellectual property, regulatory strategy, clinical development, and commercialization. Larry previously served as General Counsel and Secretary at Blue Buffalo Company, where he advised the company through its $8 billion sale to General Mills. Earlier in his career, he held increasingly senior roles at Pfizer Inc., and served as an Associate attorney at both Arnold & Porter and Weil, Gotshal & Manges. He earned his bachelor’s degree from Dartmouth College and law degree from Columbia Law School.

    Diem Nguyen, Ph.D.

      Diem Nguyen, Ph.D.
      Chief Executive Officer

      Diem Nguyen, Ph.D., began serving as Chief Executive Officer and as a Director in January 2024. Dr. Nguyen joined SIGA from Xalud Therapeutics, a clinical stage biotechnology company developing treatments for inflammatory diseases, including pain associated with osteoarthritis, and neurodegenerative diseases, where she served as CEO. Prior to Xalud, Dr. Nguyen served as executive vice president of biopharma at PPD Inc., a leading global clinical research organization providing integrated drug development services. From 2009-2018, she served in several roles at Pfizer including global president, Americas, Pfizer Essential Health, where she was responsible for diverse commercial businesses in the U.S., Latin America, Canada, and Puerto Rico representing more than $11 billion in annual revenue. She earned a Ph.D. in biochemistry and molecular genetics at the University of Virginia, as well as an M.B.A. from Darden Graduate School of Business Administration.